Hunan Hansen Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 15.00%

Hunan Hansen Pharmaceutical Co Ltd (002412) has an Asset Resilience Ratio of 15.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Hunan Hansen Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥410.02 Million
≈ $60.00 Million USD Cash + Short-term Investments

Total Assets

CN¥2.73 Billion
≈ $399.99 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Hunan Hansen Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Hunan Hansen Pharmaceutical Co Ltd assets under control.

Liquid Assets Composition Over Time

This chart breaks down Hunan Hansen Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Hunan Hansen Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥410.02 Million 15.0%
Total Liquid Assets CN¥410.02 Million 15.00%

Asset Resilience Insights

  • Good Liquidity Position: Hunan Hansen Pharmaceutical Co Ltd maintains a healthy 15.00% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Hunan Hansen Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hunan Hansen Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Hunan Hansen Pharmaceutical Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Hunan Hansen Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 12.39% CN¥333.80 Million
≈ $48.85 Million
CN¥2.69 Billion
≈ $394.08 Million
+2.81pp
2024-12-31 9.58% CN¥244.12 Million
≈ $35.72 Million
CN¥2.55 Billion
≈ $372.74 Million
+0.86pp
2023-12-31 8.73% CN¥203.87 Million
≈ $29.83 Million
CN¥2.34 Billion
≈ $341.90 Million
+2.80pp
2022-12-31 5.93% CN¥135.82 Million
≈ $19.87 Million
CN¥2.29 Billion
≈ $335.24 Million
+3.60pp
2021-12-31 2.33% CN¥49.24 Million
≈ $7.21 Million
CN¥2.11 Billion
≈ $308.95 Million
--
pp = percentage points

About Hunan Hansen Pharmaceutical Co Ltd

SHE:002412 China Drug Manufacturers - Specialty & Generic
Market Cap
$665.65 Million
CN¥4.55 Billion CNY
Market Cap Rank
#10898 Global
#3012 in China
Share Price
CN¥9.04
Change (1 day)
+2.03%
52-Week Range
CN¥5.50 - CN¥14.02
All Time High
CN¥51.53
About

Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granu… Read more